Superworth

Bristol-Myers Squibb price to free cash flow BMY

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Nov 3, 2026
n/m
a quarter missing
10-year median
11.8×
10-year range
6.1× to 111×
Peer median
14.9×

Bristol-Myers Squibb's price to free cash flow can't be checked today: its free cash flow for Q3 FY26, the quarter to Sep 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.

On the days it had one over the last ten years, its median was 11.8×, from 6.1× in Oct 2025 to 111× in Jan 2017.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.3×7.1×12.0×
20257.3×6.1×8.9×
20248.5×6.4×9.1×
20238.9×8.7×12.9×
202212.0×9.4×13.6×
20219.3×8.4×12.9×
202012.0×11.0×19.4×
201913.8×11.8×22.7×
201822.4×18.3×26.7×
201722.7×22.2×111×
2016108×93.2×117×
2015108×28.6×108×
201428.6×19.3×37.6×
201335.6×7.7×35.8×
20127.3×7.3×14.0×
201113.2×10.7×13.3×
201012.1×11.3×13.0×

Against its peers

Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.

CompanyPrice to free cash flow
BMYBristol-Myers Squibbn/m
PFEPfizer16.0×
GILDGilead Sciencesn/m
AMGNAmgen24.8×
MRKMerckn/m
BIIBBiogen13.7×
ABBVAbbVien/m
JNJJohnson & Johnsonn/m
JAZZJazz Pharmaceuticals8.7×
Peer median14.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Bristol-Myers Squibb

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.